Missing the Covid boat, Junshi stumbles back to old business
Despite developing an oral drug to treat Covid, the biotech company's revenue fell sharply and its net loss widened by nearly 40% in the first quarter Key Takeaways: Junshi Bioscience's…
Recent Articles
Missing the Covid boat, Junshi stumbles back to old business
1877.HK
688180.SHG
RELATED ARTICLES
-
As Covid drug cash dwindles, Vigonvita targets new remedies
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
-
ZTE comeback stumbles on China telecoms spending slowdown
0763.HK 000063.SHE
